Patents Examined by Nancy A Treptow
-
Patent number: 10934327Abstract: Disclosed are next-generation multi-mutated capsid protein-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using these high transduction efficiency vector constructs in a variety of therapeutic applications including, inter alia, as delivery agents for the treatment or amelioration of one or more diseases or abnormal conditions in an affected mammal using in vivo and/or ex situ viral vector-based gene therapy protocols. Also disclosed are large-scale production methods for the multi-mutated, capsid-modified rAAV expression vectors, viral particles, and infectious virions, as well as use of the disclosed compositions in the manufacture of medicaments for use in a variety of in vitro and/or in vivo therapeutic methodologies.Type: GrantFiled: November 28, 2017Date of Patent: March 2, 2021Assignee: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, Li Zhong, Sergei Zolotukhin, George Vladimirovich Aslanidi, Mavis Agbandje-McKenna, Kim M. Van Vliet, Chen Ling
-
Patent number: 10858385Abstract: Provided herein, in some embodiments, are methods and composition for the production of nucleoside triphosphates and ribonucleic acids.Type: GrantFiled: November 20, 2018Date of Patent: December 8, 2020Assignee: GreenLight Biosciences, Inc.Inventors: Drew S. Cunningham, Daniel MacEachran, James Robbins Abshire, Himanshu Dhamankar, Ifeyinwa Iwuchukwu, Mehak Gupta, Matthew Eduardo Moura, Naveen Sudharsan, Nicholas Skizim, Rachit Jain, Karthikeyan Ramachandriya
-
Patent number: 10829771Abstract: Methods and compositions are provided for displaying a protein of interest (POI) on the surface of a eukaryotic cell by fusing the POI to a signal polypeptide, a stalk polypeptide, and a surface anchor polypeptide to generate a surface accessible fusion protein. Nucleic acids are provided that include nucleotide sequences encoding a signal polypeptide, a stalk polypeptide, and a surface anchor polypeptide. In some cases, a subject nucleic acid includes and insertion site for the insertion of a POI. In some cases, a subject nucleic acid includes a nucleotide sequence that encodes a POI. In some cases a stalk polypeptide is a synthetic stalk polypeptide and various example synthetic stalk polypeptides are disclosed. In some cases, a surface anchor polypeptide is a glycosylphosphatidylinisotol (GPI) anchor domain, which can be synthetic. Kits are also provided for practicing the subject methods.Type: GrantFiled: November 9, 2015Date of Patent: November 10, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Aaron Michael Ring, Andrew Kruse, Aashish Manglik
-
Patent number: 10815279Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.Type: GrantFiled: May 24, 2018Date of Patent: October 27, 2020Assignee: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, George Vladimirovich Aslanidi, Sergei Zolotukhin, Mavis Agbandje-McKenna, Kim M. Van Vliet, Li Zhong, Lakshmanan Govindasamy
-
Patent number: 10815535Abstract: The present disclosure provides methods and kits for generating recombinant bacteriophage genomes.Type: GrantFiled: March 27, 2017Date of Patent: October 27, 2020Assignee: The Charles Stark Draper Laboratory, Inc.Inventors: Jason Holder, Connor McBrine, Sarah Gruszka, Miles Rogers, Nicole Billings
-
Patent number: 10801030Abstract: General secretory pathway (GSP) mutant Listeria bacteria are provided. Aspects of the bacteria include the presence of a GSP mutation, e.g., a SecY and/or SecA mutation. Also provided are methods of making and using the Listeria bacteria comprising a GSP mutation as vectors and vaccines expressing a heterologous nucleic acid.Type: GrantFiled: November 4, 2015Date of Patent: October 13, 2020Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Daniel A. Portnoy, Juliana Durack, Thomas P. Burke
-
Patent number: 10800818Abstract: Disclosed are compositions and methods for expressing and purifying a peptide of interest using a Flagellar Type III secretion system. Disclosed are nucleic acid sequences that contain a FlgM nucleic acid sequence, a cleavage site, and a nucleic acid sequence of interest. Also disclosed are polypeptides that contain FlgM, a cleavage site and a peptide of interest. Methods of producing polypeptides that have FlgM, a cleavage site and a peptide of interest are provided.Type: GrantFiled: March 15, 2017Date of Patent: October 13, 2020Assignee: University of Utah Research FoundationInventors: Kelly T. Hughes, Baldomero M. Olivera
-
Patent number: 10793863Abstract: The present disclosure describes genes and proteins of the coenzyme F430 synthetic pathway. The genes and proteins in the pathway find uses as isolated nucleic acids, transformation vectors, a transformation media, genetically modified cells, methods of modulating methanogenesis, methods of modulating methane oxidation, methods of making a tetrapyrrole compound, methods of oxidizing methane, methods of biogenic methane synthesis is provided, methods of assaying an organism for potential methanogenic or methanotrophic activity, and isolated proteins.Type: GrantFiled: May 5, 2017Date of Patent: October 6, 2020Assignee: AUBURN UNIVERSITYInventor: Steven Mansoorabadi
-
Patent number: 10767176Abstract: This invention pertains to modified compositions for use in CRISPR systems, and their methods of use. In particular, length-modified and chemically-modified forms of crRNA and tracrRNA are described for use as a reconstituted guide RNA for interaction with Cas9 of CRISPR systems. The resultant length-modified and chemically-modified forms of crRNA and tracrRNA are economical to produce and can be tailored to have unique properties relevant to their biochemical and biological activity in the context of the CRISPR Cas9 endonuclease system.Type: GrantFiled: October 21, 2016Date of Patent: September 8, 2020Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Michael Allen Collingwood, Ashley Mae Jacobi, Garrett Richard Rettig, Mollie Sue Schubert, Mark Aaron Behlke
-
Patent number: 10745714Abstract: Disclosed herein are Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) 9-based system related compositions and methods of using said CRISPR/Cas9-based system related compositions for altering gene expression and genome engineering. Also disclosed herein are compositions and methods of using said compositions for altering gene expression and genome engineering in muscle, such as skeletal muscle and cardiac muscle.Type: GrantFiled: May 29, 2018Date of Patent: August 18, 2020Assignee: Duke UniversityInventors: Charles A. Gersbach, Isaac B. Hilton, Pablo Perez-Pinera, Ami M. Kabadi, Pratiksha I. Thakore, David G. Ousterout, Joshua B. Black
-
Patent number: 10738314Abstract: Provided is an amino acid optimization of a functional motif on an IrrE protein of a Deinococcus geothermalis strain and homologous proteins thereof obtained by site mutation, wherein a second-site or fifth-site alanine in a functional domain motif 154LAELAR159 is mutated. into serine.Type: GrantFiled: May 9, 2016Date of Patent: August 11, 2020Assignee: BIOTECHNOLOGY RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCESInventors: Wei Zhang, Zhengfu Zhou, Ming Chen, Min Lin
-
Patent number: 10724070Abstract: Stable, constitutively expressed, chromosomal fluorescent transcriptional fusions in bacterial pathogens and methods of using the same to screen candidate compounds for anti-bacterial efficacy.Type: GrantFiled: November 14, 2013Date of Patent: July 28, 2020Assignees: University of Cincinnati, Government of the United States as Represented by the Secretary of the Air ForceInventors: Daniel J. Hassett, Shengchang Su, Thomas J. Lamkin, Roland Saldanha
-
Patent number: 10723768Abstract: Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant rAAV vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene therapy, and large-scale production of rAAV vectors.Type: GrantFiled: August 18, 2017Date of Patent: July 28, 2020Assignee: University of Florida Research Foundation, IncorporatedInventors: Li Zhong, Sergei Zolotukhin, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Arun Srivastava
-
Patent number: 10676735Abstract: Disclosed herein are methods of using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) 9-based epigenomic editing systems for high-throughput screening of regulatory element function.Type: GrantFiled: July 22, 2016Date of Patent: June 9, 2020Assignee: Duke UniversityInventors: Charles A. Gersbach, Gregory E. Crawford, Timothy E. Reddy, Tyler S. Klann
-
Patent number: 10662426Abstract: This invention relates to metabolically engineered microorganisms, such as bacterial and or fungal strains, and bioprocesses utilizing such strains. These strains enable the dynamic control of metabolic pathways, which can be used to optimize production. Dynamic control over metabolism is accomplished via a combination of methodologies including but not limited to transcriptional silencing and controlled enzyme proteolysis. These microbial strains are utilized in a multi-stage bioprocess encompassing at least two stages, the first stage in which microorganisms are grown and metabolism can be optimized for microbial growth and at least one other stage in which growth can be slowed or stopped, and dynamic changes can be made to metabolism to improve the production of desired product, such as a chemical or fuel.Type: GrantFiled: June 11, 2015Date of Patent: May 26, 2020Assignee: DUKE UNIVERSITYInventors: Michael David Lynch, Ashley Delanie Trahan, Daniel Rodriguez, Zhixia Ye, Charles Bridwell Cooper, Ahmet Bozdag
-
Patent number: 10648003Abstract: The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a Listeria monocytogenes phage recombinase, a Streptococcus pyogenes phage recombinase, a Bacillus subtilis phage recombinase, a Mycobacterium tuberculosis phage recombinase and a Mycobacterium smegmatis phaType: GrantFiled: June 8, 2018Date of Patent: May 12, 2020Assignee: Intrexon CorporationInventor: Malla Padidam
-
Patent number: 10626429Abstract: The present invention relates to methods of joining two or more double-stranded (ds) or single-stranded (ss) DNA molecules of interest in vitro, wherein the distal region of the first DNA molecule and the proximal region of the second DNA molecule of each pair share a region of sequence identity. The method allows the joining of a large number of DNA fragments, in a predetermined order and orientation, without the use of restriction enzymes. It can be used, e.g., to join synthetically produced sub-fragments of a gene or genome of interest. Kits for performing the method are also disclosed. The methods of joining DNA molecules may be used to generate combinatorial libraries useful to generate, for example, optimal protein expression through codon optimization, gene optimization, and pathway optimization.Type: GrantFiled: July 31, 2019Date of Patent: April 21, 2020Assignee: SGI-DNA, Inc.Inventors: Daniel G. Gibson, Hamilton O. Smith, Clyde A. Hutchison, Lei Young, J. Craig Venter
-
Patent number: 10624349Abstract: The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.Type: GrantFiled: November 17, 2017Date of Patent: April 21, 2020Assignee: SNIPR TECHNOLOGIES LIMITEDInventor: Jasper Clube
-
Patent number: 10604761Abstract: The present invention provides host cells for use in an inducible coexpression system that is capable of controlled induction of expression of each gene product.Type: GrantFiled: February 16, 2017Date of Patent: March 31, 2020Assignee: AbSci LLCInventors: Sean McClain, Mark Valasek
-
Patent number: 10597735Abstract: Inhibitors of the tmRNA pathway have antibacterial activity with broad species specificity, including B. anthracis and other pathogens of military and civilian interest. Identified cyclic or linear peptides are further selected by in vivo selection methods, kill bacterial pathogens when added exogenously, and/or eliminate plasmids carrying antibiotic resistance or virulence genes. The molecular target of each cyclic peptide is in the tmRNA pathway and the tmRNA pathway is inhibited in vitro and in vive by the addition of the peptides.Type: GrantFiled: December 20, 2016Date of Patent: March 24, 2020Assignee: The Penn State Research FoundationInventors: Kenneth C Keiler, Stephen J Benkovic